



Biosynthesis Hot Paper

Synthetic Biology Driven Biosynthesis of Unnatural Tropolone Sesquiterpenoids

Carsten Schotte,* Lei Li, Daniel Wibberg, Jörn Kalinowski, and Russell J. Cox*


Abstract: Tropolone sesquiterpenoids (TS) are an intriguing family of biologically active fungal meroterpenoids that arise through a unique intermolecular hetero Diels–Alder (hDA) reaction between humulene and tropolones. Here, we report on the combinatorial biosynthesis of a series of unprecedented analogs of the TS pycnidione **1** and xenovulene A **2**. In a systematic synthetic biology driven approach, we recombined genes from three TS biosynthetic gene clusters (pycnidione **1**, xenovulene A **2** and eupenifeldin **3**) in the fungal host *Aspergillus oryzae* NSARI. Rational design of the reconstituted pathways granted control over the number of hDA reactions taking place, the chemical nature of the fused polyketide moiety (tropolono- vs. monobenzo-pyranyl) and the degree of hydroxylation. Formation of unexpected monobenzo-pyranyl sesquiterpenoids was investigated using isotope-feeding studies to reveal a new and highly unusual oxidative ring contraction rearrangement.

Introduction

Tropolone sesquiterpenoids (TS) are fungal meroterpenoid natural products^[1] that display a significant array of biological activities. For example: pycnidione **1** is an anti-proliferative vs. human lung cancer cells (9 nM);^[2] xenovulene A **2** inhibits the human γ -aminobutyrate A (GABA_A) benzodiazepine receptor (40 nM);^[3] eupenifeldin **3** and neosetophome B **4** are potent antitumor agents (nanomolar activity towards human cancer cell lines);^[1,4] while epolone A **5** selectively induces erythropoietin (EPO) expression in human cells in the μ M range; (Scheme 1 A).^[5]

All tropolone sesquiterpenoids share the structural motif of a core 11-membered macrocycle (derived from humulene **6**; Scheme 1 B) connected to one or two dihydropyran rings

that link the macrocycle with polyketide-derived tropolones.^[6] The structural diversity of TS is further enhanced via: optional hydroxylation at the C-10 position (e.g. eupenifeldin **3**);^[4] different olefin configurations of the central humulene macrocycle (e.g. xenovulene B **11** vs. neosetophome B **4**);^[6] replacement of one or two tropolone moieties by monobenzo-pyranyl moieties (e.g. epolone A **5**);^[5] or



Scheme 1. A, Selected tropolone sesquiterpenoids with key structural features highlighted. Red = polyketide derived tropolones; Blue = benzopyranyl moiety; Green = optional C-10 hydroxylation; B, Hetero Diels–Alder reaction in the biosynthesis of xenovulene B **11** and neosetophome B **4**; hDA = hetero Diels–Alderase; SDR = short-chain dehydrogenase; P450 = cytochrome P450.

[*] C. Schotte, L. Li, Prof. Dr. R. J. Cox
Institute for Organic Chemistry and BMWZ
Leibniz Universität Hannover
Schneiderberg 38, 30167 Hannover (Germany)
E-mail: carsten.schotte@oci.uni-hannover.de
russell.cox@oci.uni-hannover.de

Dr. D. Wibberg, Prof. Dr. J. Kalinowski
Center for Biotechnology—CeBiTec
Universitätsstraße 27, 33615 Bielefeld (Germany)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/anie.202009914>.


© 2020 The Authors. Published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

consecutive oxidative ring contractions of the polyketide (e.g. xenovulene A **2**).^[7]

Successful total syntheses of known TS natural products have not been reported in the literature,^[8–11] suggesting that a biosynthetic approach might be more feasible to access TS scaffolds for biological testing.^[6] Biosynthetically, TS are of significant interest due to the unusual enzymology involved in the formation of the core meroterpenoid skeleton.

Fungal biosynthetic gene clusters (BGC) have been linked to the production of the two tropolone sesquiterpenoids xenovulene A **2** (*aspks1* BGC in *Sarocladium schorii* = *Acremonium strictum*) and eupenifeldin **3** (*eup* and *eupf* BGC in *Phoma* sp. and *Penicillium janthinellum*, respectively).^[6,7,12] TS biosynthesis proceeds via initial formation of stipitaldehyde **8** by cooperation of a non-reducing PKS (nrPKS, TropA), an FAD-dependent monooxygenase (FMO, TropB) and a non-haem iron dioxygenase (NHI, TropC), analogous to early biosynthetic steps in the biosynthesis of stipitatic acid (Scheme 2 and Figure S14 in the Supporting Information).^[6,7,13]

Stipitaldehyde **8** represents a branching point in TS biosynthesis (Scheme 1B): in the case of xenovulene A **2**, stipitaldehyde **8** is *oxidised* by the cytochrome P450 AsR2 to the corresponding hemiacetal **9** and subsequent elimination of water yields the reactive quino-methide **10** that undergoes an enzyme-catalyzed hetero Diels–Alder reaction with α -humulene **6**, synthesised by an unusual terpene cyclase, yielding xenovulene B **11** (Scheme 1B).^[6,7] However, during the biosynthesis of eupenifeldin **3**, stipitaldehyde **8** is *reduced* by the short-chain dehydrogenase (SDR) EupfE to the corresponding alcohol stipitol **12**. The hetero Diels–Alderase EupfF then catalyses formation of the *o*-quino-methide **13** prior to hetero Diels–Alder reaction with 10-hydroxy-humulene **7**, to give neosetophome B **4** (Scheme 1B).^[6] Notably, in vitro experiments with EupfF only gave rise to mono-substituted tropolone sesquiterpenoids and formation of bistropolones such as **1** and **3** has not yet been achieved in vitro or in vivo.^[6] Access to double hDA adducts thus represents an intriguing biosynthetic challenge; similarly, the origin and formation of TS natural products with benzene



Scheme 2. Biosynthetic routes towards tropolone sesquiterpenoids isolated in this study: **A**, each route representing an individual expression experiment in *A. oryzae* NSAR1. Compounds in blue were newly isolated in this study. Compounds in brackets were not observed; **B**, Route to **6** and **24**; **C**, incorporation of labelled sodium [1,2-¹³C₂] acetate and (*methyl*-¹³C) methionine into **21** and incorporation of labelled sodium [1,2-¹³C₂] acetate into **26**.

rings, such as epolone A **5**,^[1,14–17] has remained uninvestigated so far.

We decided to deploy a synthetic biology driven combinatorial heterologous biosynthesis approach to rationally expand the chemical space around TS natural products and to investigate key biosynthetic steps. *Aspergillus oryzae* has previously been established as an excellent host for the expression of biosynthetic gene clusters^[18–21] and recently we reconstituted the total biosynthesis of the xenovulenes therein, granting rapid access to a variety of xenovulenes on a multi-milligram scale.^[7] We reasoned that rational extension and diversification of the xenovulene A **2** biosynthetic pathway by mixing and matching genes from different TS BGC should give rise to new TS natural products and further illuminate key biosynthetic steps in TS biosynthesis. Here, we identify BGC involved in pycnidione **1** and eupenifeldin **3** biosynthesis and generate a series of new, unnatural TS analogues. Labelling studies were deployed to investigate the origin of monobenzopyranyl moieties observed in several natural and unnatural compounds and the results shed light on a new ring-contraction during their biosynthesis.

Results and Discussion

Phaeosphaeriaceae sp. CF-150626 and *Leptobacillum* sp. CF-236968 were obtained from Fundación MEDINA (Granada, Spain). *Phaeosphaeriaceae* sp. (formerly referred to as unidentified ascomycete F-150626) was previously reported to produce the bistropolone-humulene eupenifeldin **3** and the monotropolone-monobenzopyranyl-humulene noreupenifeldin **14** (Figure 1C).^[17] In our hands CF-150626 produced eupenifeldin **3** (8.7 mg L⁻¹; HRMS, [M]H⁺ calculated C₃₃H₄₁O₇ 549.2852, found 549.2856) as the major product, confirmed by full NMR characterization (Figure S24–S32 and Table S10). A second compound, satisfying the molecular weight of noreupenifeldin **14** (HRMS: [M]H⁺ calculated C₃₂H₄₁O₆ 521.2903, found 521.2907) was also produced. Purification to homogeneity (2.8 mg L⁻¹) and NMR analysis

revealed slight differences in ¹H- and ¹³C-NMR chemical shifts as compared to noreupenifeldin **14**.^[17] Full structure elucidation confirmed the compound to be a regioisomer of noreupenifeldin in which the tropolone and benzene rings are exchanged as compared to noreupenifeldin **14** (Figure S37–S45 and Table S13). Subsequent comparison with literature NMR data identified this compound as the previously described noreupenifeldin B **15** (Figure 1A).^[1] Dehydroxyeupenifeldin **16** (HRMS: [M]H⁺ calculated C₃₃H₄₀O₆ 533.2903, found 533.2912; Figure 1A) was observed as a minor component and characterized by NMR analysis (Figure S50–S57 and Table S16).

The hitherto undescribed fungus CF-236968 produced pycnidione **1** (2 mg; HRMS: [M]H⁺ calculated C₃₃H₄₁O₇ 549.2852, found 549.2853) as the dominant product, confirmed by full NMR characterization (Figure S58–S65 and Table S17). Additionally, a related compound **17** with the molecular weight of 520 (HRMS: [M]H⁺ calculated C₃₂H₄₁O₆ 521.2903, found 521.2905) was observed and purified to homogeneity. Overall, the obtained NMR data was similar, but not identical, to the previously reported epolone A **5**.^[5]

Analysis of COSY and HMBC data for **17** established the carbon skeleton of the humulene, tropolone and monobenzopyranyl moieties (Figure S66–S73 and Table S18). Among others, key HMBC/COSY correlations between H₂-9' and C-6' and between H-9' to H-1 established the tropolone ring at the western side of humulene; ¹H-¹H COSY coupling of H-8 to H₂-8'' together with ³J coupling of H₂-8'' to C-5'' placed the benzopyranyl moiety at the eastern side of humulene and confirmed the regioselectivity of the fused ring-systems as opposite to those encountered in epolone A **5**, thus establishing **17** as a novel TS that we name epolone C (Figure 1B).

Biosynthetic gene clusters involved in formation of pycnidione **1** and eupenifeldin **3**, were identified by standard Illumina paired-end sequencing which afforded high quality draft genome sequences for both fungi (e.g. CF-150626, 44.7 MBp and N₅₀ 164515; CF-236968 28.6 MBp and N₅₀ 466766; Table S3). TS BGC were identified by search for nrPKS 3-methylorcinol synthase (AsPKS1) homologs, since 3-methylorcinol is the precursor of **8**.^[7] A single *aspsk1*-like gene cluster was revealed in each fungal genome (here named *eup2* BGC [CF-150626] and *pyc* BGC [CF-236968]; Figure 2A). The Artemis comparison tool was used to visualize homologies between the two clusters and the previously reported *aspsk1* BGC from *Acremonium strictum* (Figure 2A).^[23] As expected all clusters share core genes necessary for stipitaldehyde **8** formation (*aspsk1*, *asL1*, *asL3*; *eupPKS*, *eupL1*, *eupL5*; *pycPKS*, *pycL1*, *pycL3* respectively) and additionally homologous copies of a hetero Diels–Alderase (*asR5*; *eupR1*; *pycR1*) and a humulene synthase (*asR6*; *eupR3*; *pycR6*, Table S9).

Unique to the *eup2* BGC and *pyc* BGC are short-chain dehydrogenase encoding genes (*eupL4* and *pycL2*; homologous to *eupfE*) and a cytochrome P450 (*eupR6*, *pycR5*) homologous to *eupfD*, previously shown to be responsible for C-10 hydroxylation of the terpene moiety.^[6,12] Noticeably, the ring-contraction enzymes *asL4* and *asL6* only have a single homologue in these clusters (*eupR5* and *pycR4* respectively).




Figure 1. A, tropolone sesquiterpenoids isolated from *Phaeosphaeriaceae* sp.; B, tropolone sesquiterpenoids isolated from *Leptobacillum* sp.; C, Structure of noreupenifeldin **14**.




Figure 2. A, Artemis comparison between *asps1* BGC (*Acremonium strictum*), *eup2* BGC (*Phaeosphaeriaceae* sp.) and *pyc* BGC (*Leptobacillum* sp.); B, isotopic labelling of key tropolone sesquiterpenoids with sodium [$1\text{-}^{13}\text{C}$, $2\text{-}^{13}\text{C}$, $1,2\text{-}^{13}\text{C}_2$]-labelled acetate and/or [$\text{methyl-}^{13}\text{C}$]-labelled methionine. Labelling pattern of xenovulene B **11** as described by Simpson and co-workers.^[22]

Comparison of the *eup2* BGC to the previously reported *eup* cluster in *Phoma* sp.^[12] revealed a high degree of similarity and this very strongly supported the *eup2* cluster to be responsible for the production of **3** in CF-150626. (Table S9 and Figure S15). RT-PCR further confirmed upregulation of the *eup2* BGC only under **3**-producing conditions (Figure S16).

Pycnidione **1** has been isolated from several fungal sources,^[16,24,25] but, to-date no biosynthetic gene cluster has been reported. In order to link the putative *pyc* BGC to the production of **1** we tried to genetically manipulate CF-236968. However, the fungus proved resistant to common gene disruption technologies. Furthermore, attempts to isolate RNA from the fungus failed, preventing a similar analysis by gene expression profiling as done for CF-150626. However, the high degree of homology to the *eup2* cluster and absence of any other *asps1*-like gene cluster in the genome strongly supports the *pyc* BGC to be responsible for **1** formation. Additionally, recombinant production of the putative humulene synthase PycR6 and incubation with farnesylpyrophosphate afforded α -humulene **6** as confirmed by GC/MS analysis (Figure S17–S19).

While fungal tropolone formation is well-understood, the origin of the monobenzopyran moiety in noreupenifeldin B **15** and epolone C **17** poses an intriguing biosynthetic

question. Chen and co-workers as well as Zhang and co-workers recently proposed a hetero Diels–Alder reaction between humulene and an *o*-quinomethide (derived from orsellinaldehyde) to explain the presence of the benzopyran moiety.^[26,27] Orsellinaldehyde is a common fungal metabolite and has been identified as the tetraketide product of an nrPKS.^[28] However, no biosynthetic evidence to support such an hDA reaction has been reported so far. To establish the biosynthetic origin of the benzopyran moiety we performed incorporation studies with ^{13}C -labelled acetates. In separate experiments we fed CF-150626 with [$1\text{-}^{13}\text{C}$]- and [$2\text{-}^{13}\text{C}$]-labelled acetates (Figure 2B). ^{13}C -NMR of purified **3** showed that 31/33 carbon signals were enhanced, and the obtained labelling pattern of terpene and tropolone parts was identical as previously reported for xenovulene B **11** (Figure S33–S36 and Table S11 + S12).^[22] Only the NMR signals for carbons C-3' and C-3'' (within the two tropolone rings) were not enhanced, in agreement with their proposed origin from methionine.^[29]

In the case of noreupenifeldin B **15** 30/32 carbon signals were enhanced (Figure 2B). The observed pattern of label incorporation in the tropolone and humulene was the same as in eupenifeldin **3**: all carbon signals except the signal for C-3' of the tropolone were enhanced (Figure S46–S49 and Table S14 + S15). Surprisingly, carbons C-6'' and C-1'' were both derived from [$2\text{-}^{13}\text{C}$]-acetate, while the signal for C-2'' was not derived from acetate. This suggests that C-2'' is derived from methionine. C-6'' and C-1'' being both derived from [$2\text{-}^{13}\text{C}$]-acetate indicate that one acetate was disrupted during the biosynthesis of the benzopyran moiety of noreupenifeldin B **15**. A putative orsellinaldehyde precursor would show intact labelling for four sequential intact acetate units and is thus eliminated as a possible precursor to **15**.

Contrary to previous suggestions, the labelling data suggests that **15** is derived from a ring-contraction of a tropolone precursor (probably eupenifeldin **3**), instead of originating from an hDA reaction between humulene and a benzylic *o*-quinomethide. Notably, both the *eup2* and *pyc* BGC each include a gene homologous to *asL4* and *asL6* (*eupR5*, *pycR4*). *AsL4* and *AsL6* are FAD-dependent oxygenases known to catalyze regioselective oxidative ring contractions during the biosynthesis of xenovulene A **2**, and thus represent possible candidates to catalyze such a reaction.^[7] Attempts to probe the role of PycR4, *AsL4* and *AsL6* in vitro were prevented in this study (and previously) by the inability to obtain soluble protein preparations.^[7] Furthermore, knockout and silencing experiments to probe the role of these genes is not currently possible since the host organisms cannot yet be transformed.

We next devised expression experiments in an attempt to generate novel unnatural derivatives (Table 1). Previously we reported on the heterologous production of xenovulene B **11** and xenovulene A **2** in *A. oryzae* NSAR by co-expressing six or eight biosynthetic genes, respectively, using the modular expression system established by Lazarus and co-workers (Table 1, Exp. Xen B and Xen A respectively).^[7,30] A series of additional *A. oryzae* NSAR1 expression plasmids comprising key biosynthetic genes from the *eup2* and *pyc* BGC were generated using standard yeast homologous recombination/

Table 1: Overview of performed heterologous expression experiments. Exp. Xen. B and Xen. A previously reported.^[7] PKS = polyketide synthase; FMN = FAD-dependent monooxygenase; NHI = non-haem iron dioxygenase; P450 = cytochrome P450 monooxygenase; hDA = hetero Diels–Alderase; Hum = humulene synthase; RC = ring-contraction enzyme; SDR = short-chain dehydrogenase. Red shading = genes from *asps1* BGC; Blue shading = genes from *pyc* BGC; green shading = genes from *eup2* BGC. Red = isolated and fully characterised for the first time.

Expt		Xen. B ^[7]	Xen. A ^[7]	1	2	3	4	5	6	7	8	9
Gene	Func.											
<i>asps1</i>	PKS	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
<i>asL1</i>	FMN	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
<i>asL3</i>	NHI	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
<i>asR2</i>	P450	✓	✓	✓	✓	✓						
<i>asR5</i>	hDA	✓	✓	✓	✓	✓	✓	✓				
<i>asR6</i>	Hum	✓	✓	✓	✓	✓	✓	✓				
<i>asL4</i>	RC		✓									
<i>asL6</i>	RC		✓		✓							
<i>pycR1</i>	hDA											✓
<i>pycR6</i>	Hum											✓
<i>eupL4</i>	SDR						✓	✓		✓	✓	✓
<i>eupR1</i>	hDA								✓	✓	✓	
<i>eupR3</i>	Hum								✓	✓	✓	
<i>eupR5</i>	RC					✓						✓
<i>eupR6</i>	P450			✓	✓			✓				✓
Products		11	2	11 18	2	11 19 20	21 22 23 24					25 26

Gateway technology. Ectopic integration of biosynthetic genes into *A. oryzae* NSAR1 gDNA was confirmed by PCR analysis (Figure S5–S13).

We began by introducing modifications into the existing biosynthetic route to xenovulene B **11**. Hydroxylation at C-10 of α -humulene is a recurring feature in bistropolones^[4,25] but has never been observed in the xenovulenes. Co-expression of the xenovulene B **11** producing genes with the humulene hydroxylase encoding gene *eupR6* (Exp.1, Table 1) and analysis by LCMS showed production of xenovulene B **11** and a new compound **18** (Figure 3, Exp. 1; Scheme 2 A), with a 16 amu difference relative to xenovulene B **11** (nominal mass 382) as observed by HRMS ($[M]H^+$ calculated $C_{24}H_{31}O_4$ 399.2171 found 399.2174). As expected, NMR structure elucidation revealed the C-10 methylene observed in xenovulene B **11** (δ_H 2.12/2.26; δ_C 38.0) to be replaced by a downfield shifted oxygenated carbon (δ_H 4.36; δ_C 77.1) in **18** and confirmed **18** as 10-hydroxyxenovulene B (Figure S74–S82 and Table S19). The relative stereochemistry of **18** was determined by NOESY-NMR; absence of correlation between H₃-12 and H-1 established these to be *trans*. H₃-12 NOE correlation to H-9', H₂-3 and H₂-11, but not H-10, places H₃-12 and OH-10 on the same face.

Surprisingly, inclusion of the ring-contraction encoding genes *asL4* and *asL6* in the expression system (Exp. 2, Table 1) led only to the production of xenovulene A **2** (Figure S20) but not to production of any hydroxylated analogue of **2**, suggesting that ring-contraction might out-compete hydroxylation of the humulene moiety and that the




Figure 3. Heterologous expression of key biosynthetic gene combinations in *Aspergillus oryzae* NSAR1. Shown are LC/MS diode array (DAD) traces of extracts of representative transformants.

fully ring-contracted scaffold of xenovulene A **2** is not a possible substrate for hydroxylation.

The known ring-contraction enzymes *AsL4* and *AsL6* from the *asps1* BGC show 34.8% and 31.8% sequence identity to *EupR5* encoded in the *eup2* cluster. Recently, Che and co-workers proposed the *EupR5* homologue *EupH* to be a putative redox partner of the humulene hydroxylase present in all eupenifeldin BGC.^[12] However, the distinct sequence homology of *EupR5* to the known ring-contraction enzymes *AsL4* and *AsL6* prompted us to hypothesise that *EupR5* might catalyse a similar reaction in CF-150626—given the observation of a ring-contraction during **15** biosynthesis.

To probe the biosynthetic role of *EupR5* we co-expressed the xenovulene B **11** producing genes with *eupR5* in *A. oryzae* (Exp. 3, Table 1). Analysis of transformants revealed the formation of two compounds, **19** and **20**, both having the nominal mass of 370 (HRMS: $[M]H^+$ calculated $C_{23}H_{31}O_4$ 371.2222 found 371.2218 and 371.2227; Figure 3; Exp. 3). A 12 amu difference compared to xenovulene B **11** (382) was consistent with a ring contraction. Purification to homogeneity by preparative LCMS of both compounds individually failed as the difference in retention time was too small. However, NMR characterization of a mixture of **19** and **20** was sufficient to quickly identify **19** and **20** as the previously reported products of *AsL4* (**19**) and *AsL6* (**20**, previously only available in trace amounts) observed during the biosynthesis of xenovulene A **2** (Scheme 2 A, Figure S83–S92 and Table S20).^[7] Exp. 3 clearly demonstrates the ability of *EupR5* to catalyse oxidative ring-contractions *in vivo*.

Based on existing biosynthetic knowledge, the biosynthesis of xenovulene A **2** and eupenifeldin **3** diverges after formation of stipitaldehyde **8** (Scheme 1 B). We hypothesised that replacement of *asR2* by the SDR gene *eupL4* might

redirect xenovulene A **2** biosynthesis in the direction of mono- or bistropolones lacking the characteristic tetrahydrofuran ring present in all xenovulenes (Exp.4, Table 1). Analysis of transformants by LCMS analysis confirmed their inability to produce any xenovulenes as was expected by omission of *asR2*, halting the biosynthesis prior to the hDA reaction. Instead, a single new compound **21** was produced in excellent titres. HRMS analysis of **21** (HRMS: $[M]H^+$ calculated $C_{23}H_{33}O_2$ 341.2481 found 341.2481) suggested a molecular formula of $C_{23}H_{33}O_2$. Surprisingly, the nominal mass of 340 was too small to correspond to either a mono- or bistropolone TS. Purification to homogeneity (3.4 mg) and subsequent analysis by full NMR spectroscopy elucidated the structure of **21**.

Key tropolone NMR signals (e.g. characteristic aromatic protons at 6.9–7.2 ppm; aromatic methyl singlet at 2.4 ppm; carbonyl signal at 170 ppm) were replaced by aromatic protons at 6.18 ppm (H-2') and 6.25 ppm (H-6') and together with an aromatic methyl singlet at 2.19 ppm (H₃-7') indicated substitution of the usual tropolone by a benzene. Key HMBC correlations from H₂-8' to C-11, C-3' and C-5' respectively further corroborated the structure of **21**. Selective 1D-NOE experiments confirmed absence of coupling between H₃-12 and H-1 and, together with 2D-NOESY data, established the relative stereochemistry at the humulene/dihydropyran ring junction as *trans*, in agreement with biosynthetic considerations (Figure S93–S103 and Table S21).

Further inclusion of the humulene hydroxylase gene *eupR6* in the expression system (Table 1, Exp. 5) led to formation of two additional compounds (**22**, **23**), both having a nominal mass of 356 respectively (HRMS $[M]H^+$ calculated $C_{23}H_{33}O_3$ 357.2430 found 357.2428 (**22**) and 357.2431 (**23**)) consistent with **22** and **23** being hydroxylated derivatives of **21**. Indeed, purification to homogeneity (2.8 mg, 4.4 mg) and subsequent full NMR characterization revealed that the C-10 methylene group in **21** (δ_C 37.9 ppm; δ_H 1.83 and 2.10 ppm) was replaced by downfield shifted oxygenated carbons in both **22** (δ_C 78.4 ppm; δ_H 3.99 ppm) and **23** (δ_C 73.9 ppm; δ_H 4.35 ppm, Figure S105–S131 and Table S23 + S24). **22** and **23** comprise the same structural skeleton as the previously reported Pughinin A, isolated from the fungus *Kionochaeta pughii* BCC 3878.^[16] However, small differences in 1H and ^{13}C NMR shifts suggest **22** and **23** to be stereoisomers of Pughinin A. A series of 1D-NOE experiments was performed to establish the relative stereochemistry of **22** and **23**. For **22**, correlation of H-10 to H-1 and H-8'b and *vice versa* suggested H-1, H-8'b and H-10 to be on the same face. Absence of correlation from H₃-12 to either H-1, H-10 or H-8'b confirmed *trans*-fusion of the humulene/dihydropyran ring (Figure 4). Compared to **22**, compound **23** displayed significant differences in 1H -NMR chemical shift: most notably both H-10 (δ_{H-10} 4.35 ppm in **23**; δ_{H-10} 3.99 ppm in **22**) and H-1 (δ_{H-1} 2.05 ppm in **22**; δ_{H-1} 1.69 ppm in **23**) were shifted downfield by 0.36 ppm. Absence of nOe correlations between H₃-12 and H-1, H-10 and H-8'b confirmed *trans*-fusion of the humulene/dihydropyran ring. Contrary to **22**, H-10 did not correlate to H-1 whereas H-1 still correlated to H-8'b and *vice versa*. Together this nOe data suggests that in **23** the 10-hydroxy moiety faces in the opposite direction as observed in **22**. This




Figure 4. Structure elucidation of **22** and **23**. See Supporting Information for detailed structure elucidation of all other compounds. 3D model structures of **22** and **23** were calculated using Spartan 18 and minimised using molecular mechanics.

finding is further supported by careful comparison of 1H -NMR shifts of H-1 in **1**, **3**, **15–21**. Not surprisingly in all compounds with H-1 and OH-10 on the same face δ_{H-1} was found to be > 2.00 ppm whereas in compounds with H-1 and OH-10 on different faces δ_{H-1} was typically found to be < 1.90 ppm.

As a co-metabolite, humulene derivative **24** (Scheme 2B) was concomitantly produced with **22** and **23** and purified to homogeneity (4 mg; HRMS: $[M-H_2O]H^+$ calculated $C_{15}H_{23}O$ 219.1749 found 219.1749). NMR analysis confirmed **24** to be the 1,2-epoxy-10-hydroxy derivative of humulene **6** (Figure S132–S140 and Table S25) and was similar to data previously reported for phomanoxide (Figure S133).^[31] Contrary to compound **24**, phomanoxide harbours an additional epoxide at C-4/C-5. We thus name compound **24** phomanoxide B. Interestingly, trace amounts of **22**, **23** and **24** were also observed in Exp. 4, lacking the co-expressed humulene hydroxylase *eupR6*. Given the wealth of native cytochromes P450 present in *Aspergillus oryzae* NSAR1 (ca. > 150) it seems likely that a native oxygenase can hydroxylate the TS scaffold albeit to a significantly lower degree.^[32]

The results of experiments 1–5 (Table 1) demonstrated the feasibility to engineer the biosynthesis of xenovulenes, resulting in the successful generation of **18–24**. Notably, despite introduction of humulene hydroxylase *EupR6*, and short-chain dehydrogenase *EupL4*, all transformants solely produced mono-substituted Diels–Alder adducts, suggesting that the xenovulene A **2** hDA enzyme *AsR5* is limited in regard to the number of hDA reactions it catalyses. We reasoned that exchange of *AsR5* for an hDA enzyme from the eupenifeldin (*EupR1*) or pycnidione (*PycR1*) pathway might redirect the pathway to the production of bistropolones. However, omission of *asR2* and replacement of *asR5* and *asR6* for *eupR1* and *eupR3* did not lead to production of any tropolone sesquiterpenoids (Table 1, Exp. 6; Figure S21). Further inclusion of short-chain dehydrogenase encoding

gene *eupL4* (Table 1, Exp. 7; Figure S22) and humulene hydroxylase *eupR6* and FAD-dependent monooxygenase *eupR5* (Table 1, Exp. 8; Figure S23) in the expression also did not lead to production of the desired meroterpenoids.

Omission of *asR2* and introduction of hetero Diels–Alderase and terpene cyclase encoding genes *pycR1* and *pycR3* from the pycnidione pathway instead of *eupR1* and *eupR3* proved more successful (Exp. 9). Analysis of transformants by LCMS analysis identified the production of two new compounds (**25**, **26**) compared to a WT control (Figure 3). The nominal mass (532, Figure S142) and UV spectrum of minor component **25** was consistent with a bistropolone lacking the C-10 hydroxyl group. Indeed, purification of compound **25** and NMR characterization established the structure of **25** (Figure S141–S147; Table S26): key aromatic $^1\text{H-NMR}$ signals at 7.33/7.27/7.17/7.15 ppm together with two aromatic methyl group signals at 2.50 ppm and 2.43 ppm were characteristic for the presence of two tropolone rings. Key COSY and HMBC correlations further confirmed the structure of **25**.


Purification of major component **26** to homogeneity afforded 4 mg ($[\text{M}]_{\text{H}^+}$ calculated $\text{C}_{32}\text{H}_{41}\text{O}_5$ 505.2954 found 505.2941) and subsequent NMR analysis confirmed its structure. Key tropolone NMR signals including aromatic protons at 7.08 ppm and 7.22 ppm and a methyl singlet at 2.41 ppm established the presence of one tropolone ring; key HMBC correlations from $\text{H}_2\text{-9}''$ to C-7, C-9, C-4'' and C-6'' placed the tropolone ring at the eastern side of humulene. Additional aromatic proton signals at 6.14 and 6.25 ppm together with an aromatic methyl group at 2.21 ppm confirmed replacement of the second tropolone ring by a benzene. HMBC correlations of $\text{H}_2\text{-8}'$ to C-2, C-11, C-3' and C-5' further corroborated the structure and placed the benzene ring at the western face of humulene (Figure S148–S156 and Table S27). Absence of NOESY correlations between H-1 and $\text{H}_3\text{-12}$ as well as between H-8 and $\text{H}_3\text{-15}$ together with other NOESY correlations established the relative stereochemistry at the ring-junctions to be *trans*, in agreement with biosynthetic considerations.

Surprisingly, both Exp. 4 and Exp. 9 afforded TS natural products (**21**, **26**) with a benzene ring instead of the expected tropolone moiety, despite the reconstituted pathways containing no ring-contraction enzyme. In order to establish the biosynthetic origin of these 6-membered rings in *A. oryzae* we performed labelling experiments using $[1,2\text{-}^{13}\text{C}]$ -labelled acetate. Labelled **21** and **26** were analysed by $^{13}\text{C-NMR}$ (Figure S104 + S157–S158 and Table S22 + S28). Analysis of coupling constants quickly identified integration of intact acetate units. For both compounds the labelling pattern of the benzopyranol moieties were identical, comprising three intact acetate units ($\text{C}_7\text{-C}_5$, $\text{C}_6\text{-C}_1$ and $\text{C}_4\text{-C}_8$). Instead of a fourth intact acetate unit, both C-2' and C-3' did not show coupling to any other carbon atom. We reasoned that the obtained labelling pattern was in agreement with the six-membered ring in **21** and **26** being derived from a ring-contraction of a tropolone precursor, resulting in rearrangement of one acetate unit and C-2' to be derived from methionine. To probe this hypothesis, we fed $[\text{methyl-}^{13}\text{C}]$ -labelled methionine to the **26** producing strain.

Purification of labelled **26** and subsequent analysis by $^{13}\text{C-NMR}$ showed signal enhancement for two carbon signals, corresponding to C-3'' (within the tropolone ring) and C-2' (within the benzene ring, Figure S159–S161). The obtained labelling pattern thus demonstrates that **26** (and **21** accordingly) are derived from a ring-contraction of a tropolone precursor—it is therefore highly likely that **26** is derived from **25**. Benzopyran **21** is therefore most likely derived from an unobserved tropolonopyran precursor **27** (Scheme 2 A).

Significantly, the labelling pattern of the six-membered ring in **21** and **26** differs from labelling pattern of the six-membered ring in noreupenifeldin B **15** (Scheme 3). For **21** and **26**, ring contraction in *A. oryzae* must proceed via excision of the C-2' carbon in **27** and **25** respectively, whereas ring contraction of **3** in CF-150626 must proceed via excision of the C-1'' (Scheme 3 A). In the absence of a transformed ring-contraction enzyme in Exp. 5 and Exp. 9 we reasoned that *Aspergillus oryzae* NSAR1 itself must contain a putative ring-contraction enzyme, but the identity of this enzyme remains unknown. Notably, the ring-contraction by *A. oryzae* is only observed for compound **21** and **26** but not for xenovulene B **11**, which is stable in *A. oryzae* albeit it also comprises an intact tropolone ring. Structurally, xenovulene B **11** differs from **21** and **26** by the tetrahydrofuran ring characteristic of all xenovulenes and it appears that the putative ring-contraction enzyme in *A. oryzae* does not accept these as substrates. Furthermore, the observed ring-contractions in *A. oryzae* and also in *Phaeosphaeriaceae* sp. appear to be highly regioselective as in *A. oryzae* only tropolone rings on the western face of humulene are contracted whereas in *Phaeosphaeriaceae* sp. the ring-contraction occurs on the eastern side of humulene. These ring contractions also differ from those observed to be performed by AsL4 and AsL6 in the xenovulene pathway, and EupR5 observed here (Scheme 2). AsL4, AsL6 and EupR5 catalyse an oxidative ring contraction which leaves a hydroxyl group on the benzene ring, for example, **19** and **20**, whereas **15**, **21** and **26** do not contain additional oxygen.

We previously suggested a mechanism which would explain the retention of oxygen (Scheme 3 C) in the case of xenovulene A **2** biosynthesis.^[7] It is possible that the production of **15**, **21** and **26** could proceed via a similar mechanism to **19** and **20**, followed by a reductive step. However, we did not observe any intermediates which might support this possibility. Alternatively, a different FAD-dependent mechanism could be in play (Scheme 3 D), involving a ring-opening-ring-closing sequence which would explain the observed labelling and oxygenation patterns in *A. oryzae*. A similar mechanism involving initial attack at C-2'' of **3** would explain the observed labelling pattern in **15**. Tropolone ring-opening mechanisms have been suggested during the biosynthesis of phomanolides C-F.^[27] Chemical investigations by Ito support the initial oxidative ring expansion in this possibility.^[33] However, in the absence of additional information the precise origin and mechanism of these new transformations remains to be determined.



Scheme 3. Proposed ring-contraction in the biosynthesis of noreupenifeldin B **15**, **26** and **21** based on observed labelling patterns: **A**, ring-contraction in *Phaeosphaeriaceae* sp. CF-150626 proceeding via excision of carbon C-1'' in **3**; **B**, ring-contraction in *A. oryzae* proceeding via excision of carbon C-2' in **25** and **27** respectively; **C**, proposed mechanism for AsL4/AsL6/EupR5; **D**, possible process for the formation of **15**, **21** and **26** which is consistent with the observed labelling pattern, X = unknown activation.

Conclusion

Here, we report on the identification of the *eup2* and *pyc* BGC, responsible for formation of eupenifeldin **3** and pycnidione **1** in CF-150626 and CF-236968 for the first time. We successfully engineered *A. oryzae* NSAR1 for the heterologous production of seven new unnatural tropolone sesquiterpenoids in good yields, by exploiting a systematic combinatorial biosynthesis approach, demonstrating the

power of heterologous expression in fungi for the rational creation of new compounds. In this case synthetic biology outperforms synthetic chemistry which has not yet been used for the synthesis of these or related natural products. Furthermore, the heterologous expression system deployed was successfully used to determine the biosynthetic function of proteins with previously unknown activity (e.g. EupR5). This work also shows that the hDa enzymes differ in their ability to produce *mono* (e.g. AsR5) and *di*-tropolone (e.g. PycR1) meroterpenoids. We also showed that benzopyranol moieties are derived via a ring-contraction of a tropolone precursor instead of the previously suggested hDa reaction with an orsellinaldehyde. Surprisingly, *Aspergillus oryzae* NSAR1 is capable of catalyzing a similar ring-contraction, although the conducted labelling studies demonstrate, that the mechanism must differ from that previously observed during the biosynthesis of xenovulene A catalysed by AsL4/AsL6, or by EupR5. Given the wealth of potent biological activity present in naturally occurring TS natural products, this work paves the way to systematically assess TS natural products and to construct a compound library to be tested for additional/improved biological activity.

Acknowledgements

CS thanks Leibniz University for funding. LL thanks the Chinese Scholarship Council for funding (CSC 201704910820). Fundación MEDINA (Olga Genilloud/Víctor González Menéndez) are thanked for strains and culturing conditions. Jörg Fohrer and Luca Codutti are thanked for assisting with 2D-nOe data. DFG is thanked for the provision of NMR and LCMS equipment (INST 187/621-1, INST 187/686-1). Open access funding enabled and organized by Projekt DEAL.

Conflict of interest

The authors declare no conflict of interest.

Keywords: biosynthesis · meroterpenoid · pathway engineering · ring contraction · tropolone

- [1] T. El-Elimat, H. A. Raja, S. Ayers, S. J. Kurina, J. E. Burdette, Z. Mattes, R. Sabatelle, J. W. Bacon, A. H. Colby, M. W. Grinstaff, et al., *Org. Lett.* **2019**, *21*, 529–534.
- [2] C.-J. Hsiao, S.-H. Hsiao, W.-L. Chen, J.-H. Guh, G. Hsiao, Y.-J. Chan, T.-H. Lee, C.-L. Chung, *Chem.-Biol. Interact.* **2012**, *197*, 23–30.
- [3] P. Thomas, H. Sundaram, B. J. Krishek, P. Chazot, X. Xie, P. Bevan, S. J. Brocchini, C. J. Latham, P. Charlton, M. Moore, et al., *J. Pharmacol. Exp. Ther.* **1997**, *282*, 513–520.
- [4] F. Mayerl, Q. Gao, S. Huang, S. E. Klohr, J. A. Matson, D. R. Gustavson, D. M. Pirnik, R. L. Berry, C. Fairchild, W. C. Rose, *J. Antibiot.* **1993**, *46*, 1082–1088.
- [5] P. Cai, D. Smith, B. Cunningham, S. Brown-Shimer, B. Katz, C. Pearce, D. Venables, D. Houck, *J. Nat. Prod.* **1998**, *61*, 791–795.

- [6] Q. Chen, J. Gao, C. Jamieson, J. Liu, M. Ohashi, J. Bai, D. Yan, B. Liu, Y. Che, Y. Wang, et al., *J. Am. Chem. Soc.* **2019**, *141*, 14052–14056.
- [7] R. Schor, C. Schotte, D. Wibberg, J. Kalinowski, R. J. Cox, *Nat. Commun.* **2018**, *9*, 1963.
- [8] R. M. Adlington, J. E. Baldwin, G. J. Pritchard, A. J. Williams, D. J. Watkin, *Org. Lett.* **1999**, *1*, 1937–1939.
- [9] J. E. Baldwin, A. V. W. Mayweg, K. Neumann, G. J. Pritchard, *Org. Lett.* **1999**, *1*, 1933–1935.
- [10] R. M. Adlington, J. E. Baldwin, A. V. W. Mayweg, G. J. Pritchard, *Org. Lett.* **2002**, *4*, 3009–3011.
- [11] P.-J. Li, G. Dräger, A. Kirschning, *Org. Lett.* **2019**, *21*, 998–1001.
- [12] Y. Zhai, Y. Li, J. Zhang, Y. Zhang, F. Ren, X. Zhang, G. Liu, X. Liu, Y. Che, *Fungal Genet. Biol.* **2019**, *129*, 7–15.
- [13] J. Davison, A. al Fahad, M. Cai, Z. Song, S. Y. Yehia, C. M. Lazarus, A. M. Bailey, T. J. Simpson, R. J. Cox, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 7642–7647.
- [14] H. Weenen, M. H. H. Nkunya, A. A. El-Fadl, S. Harkema, B. Zwanenburg, *J. Org. Chem.* **1990**, *55*, 5107–5109.
- [15] T. Bunyapaiboonsri, S. Veeranondha, T. Boonruangprapa, S. Somrithipol, *Phytochem. Lett.* **2008**, *1*, 204–206.
- [16] P. Pittayakhajonwut, M. Theerasilp, P. Kongsaree, A. Rungrod, M. Tanticharoen, Y. Thebtaranonth, *Planta Med.* **2002**, *68*, 1017–1019.
- [17] S. Ayers, D. L. Zink, J. S. Powell, C. M. Brown, A. Grund, G. F. Bills, G. Platas, D. Thompson, S. B. Singh, *J. Nat. Prod.* **2008**, *71*, 457–459.
- [18] T. Itoh, K. Tokunaga, Y. Matsuda, I. Fujii, I. Abe, Y. Ebizuka, T. Kushiro, *Nat. Chem.* **2010**, *2*, 858–864.
- [19] L. Kahlert, E. F. Bassiony, R. J. Cox, E. J. Skellam, *Angew. Chem. Int. Ed.* **2020**, *59*, 5816–5822; *Angew. Chem.* **2020**, *132*, 5865–5871.
- [20] R. Nofiani, K. de Mattos-Shiple, K. E. Lebe, L. C. Han, Z. Iqbal, A. M. Bailey, C. L. Willis, T. J. Simpson, R. J. Cox, *Nat. Commun.* **2018**, *9*, 1–11.
- [21] Y. Matsuda, T. Wakimoto, T. Mori, T. Awakawa, I. Abe, *J. Am. Chem. Soc.* **2014**, *136*, 15326–15336.
- [22] M. E. Raggatt, T. J. Simpson, M. Ines Chicarelli-Robinson, *Chem. Commun.* **1997**, 2245–2246.
- [23] T. J. Carver, K. M. Rutherford, M. Berriman, M. A. Rajandream, B. G. Barrell, J. Parkhill, *Bioinformatics* **2005**, *21*, 3422–3423.
- [24] S. Pornpakakul, S. Roengsumran, S. Deechangvipart, A. Petsom, N. Muangsins, N. Ngamrojanavanich, N. Sriubolmas, N. Chaichit, T. Ohta, *Tetrahedron Lett.* **2007**, *48*, 651–655.
- [25] G. H. Harris, K. Hoogsteen, K. C. Silverman, S. L. Raghoobar, G. F. Bills, R. B. Lingham, J. L. Smith, H. W. Dougherty, C. Cascales, F. Peláez, *Tetrahedron* **1993**, *49*, 2139–2144.
- [26] S. Chen, Z. Liu, H. Tan, Y. Chen, S. Li, H. Li, S. Zhu, H. Liu, W. Zhang, *Org. Chem. Front.* **2020**, *7*, 557–562.
- [27] J. Zhang, Y. Li, F. Ren, Y. Zhang, X. Liu, L. Liu, Y. Che, *J. Nat. Prod.* **2019**, *82*, 1678–1685.
- [28] M. Ahuja, Y. M. Chiang, S. L. Chang, M. B. Praseuth, R. Entwistle, J. F. Sanchez, H. C. Lo, H. H. Yeh, B. R. Oakley, C. C. C. Wang, *J. Am. Chem. Soc.* **2012**, *134*, 8212–8221.
- [29] R. Bentley, *J. Biol. Chem.* **1963**, *238*, 1895–1902.
- [30] M. N. Heneghan, A. A. Yakasai, L. M. Halo, Z. Song, A. M. Bailey, T. J. Simpson, R. J. Cox, C. M. Lazarus, *ChemBioChem* **2010**, *11*, 1508–1512.
- [31] J. Zhang, L. Liu, B. Wang, Y. Zhang, L. Wang, X. Liu, Y. Che, *J. Nat. Prod.* **2015**, *78*, 3058–3066.
- [32] K. H. M. Nazmul Hussain Nazir, H. Ichinose, H. Wariishi, *Arch. Microbiol.* **2010**, *192*, 395–408.
- [33] M. Hirama, S. Itô, *Tetrahedron Lett.* **1976**, *17*, 2339–2342.

Manuscript received: July 21, 2020

Accepted manuscript online: September 15, 2020

Version of record online: October 26, 2020